Reproductive Endocrinology Practice Questions

Q: Selective estrogen receptor modulators (SERMs) are used as add-back therapy concurrently with GnRH agonist to:

Prevent bone loss. ### Explanation **Concept Overview:** GnRH agonists (e.g., Leuprolide) induce a state of **"pseudomenopause"** by downregulating pituitary GnRH receptors, leading to profound hypoestrogenism. While effective for treating endometriosis and leiomyoma, long-term use (beyond 6 months) is limited by severe side effects, most notably **accelerated bone mineral density (BMD) loss** and vasomotor symptoms. **Why Option B is Correct:** To mitigate these side effects, **"Add-back therapy"** is employed. While traditional add-back therapy uses low-dose estrogen/progestin, **SERMs (like Raloxifene)** are increasingly used. Raloxifene acts as an **estrogen agonist in the bone**, stimulating osteoblastic activity and inhibiting osteoclasts, thereby **preventing bone loss** without stimulating the endometrium or breast tissue. **Why Other Options are Incorrect:** * **Option A:** GnRH agonists alone cause leiomyoma shrinkage. Adding a SERM does not synergistically increase shrinkage; in fact, the goal of add-back is to manage side effects, not enhance primary efficacy. * **Option C:** While estrogen/progestin add-back treats vasomotor symptoms (hot flashes), **SERMs (especially Raloxifene) can actually worsen hot flashes** due to their estrogen antagonist effect in the CNS. * **Option D:** SERMs are associated with an **increased risk** of venous thromboembolism (VTE), similar to oral contraceptives; they do not decrease this risk. **High-Yield Clinical Pearls for NEET-PG:** * **The "Estrogen Threshold Hypothesis":** There is a therapeutic window (estrogen levels of 30–45 pg/mL) where bone loss is prevented, but the growth of endometriosis/fibroids is not stimulated. * **Indications for Add-back:** Usually started if GnRH agonist therapy is planned for **>6 months**. * **Raloxifene vs. Tamoxifen:** Raloxifene is preferred in add-back therapy because it is an antagonist at the uterus (no risk of endometrial hyperplasia), unlike Tamoxifen.

Q: Which of the following medications is NOT used for the management of hirsutism in females?

Oxandrolone. **Explanation:** Hirsutism is defined as the presence of terminal hair in females in a male-pattern distribution, typically caused by hyperandrogenism. The management involves blocking androgen production or inhibiting androgen action at the hair follicle. **Why Oxandrolone is the Correct Answer:** **Oxandrolone** is an **anabolic steroid** (a synthetic derivative of testosterone). Instead of treating hirsutism, it would actually **cause or worsen** it as a side effect (virilization). It is medically used to promote weight gain after surgery or chronic trauma, but it is contraindicated in the management of hyperandrogenic symptoms. **Analysis of Incorrect Options:** * **Spironolactone (Option A):** An aldosterone antagonist that also acts as a competitive androgen receptor blocker and inhibits 5-alpha reductase. It is often the first-line medical treatment for hirsutism. * **Finasteride (Option C):** A 5-alpha reductase inhibitor that prevents the conversion of Testosterone to the more potent Dihydrotestosterone (DHT). It is highly effective in reducing terminal hair growth. * **Flutamide (Option D):** A pure non-steroidal anti-androgen that competes with testosterone and DHT for binding to the androgen receptor. While effective, its use is limited by potential hepatotoxicity. **NEET-PG High-Yield Pearls:** * **Ferriman-Gallwey Score:** Used to clinically grade hirsutism; a score ≥8 is generally considered diagnostic. * **Combined Oral Contraceptives (COCs):** Usually the first-line therapy for hirsutism as they suppress ovarian androgen production and increase Sex Hormone Binding Globulin (SHBG). * **Eflornithine:** A topical cream used as an adjuvant; it inhibits the enzyme ornithine decarboxylase in hair follicles to slow hair growth. * **Contraindication:** All anti-androgens (Options A, C, D) are contraindicated in pregnancy due to the risk of feminization of a male fetus.

Q: In a patient with secondary amenorrhea who fails to achieve withdrawal bleeding after estrogen and progesterone therapy, the primary cause lies at which level?

Endometrium. ### Explanation The evaluation of secondary amenorrhea follows a stepwise approach. When a patient fails to bleed after a **Progesterone Challenge Test**, it indicates either low endogenous estrogen or an anatomical defect. To differentiate these, the **Estrogen-Progesterone (E+P) Challenge Test** is performed. **Why the Endometrium is the correct answer:** The E+P challenge involves administering exogenous estrogen to proliferate the endometrium, followed by progesterone to induce withdrawal bleeding. If the patient **fails to bleed** even after this combined therapy, it confirms that the "outflow tract" or the "target organ" is defective. This implies the endometrium is either absent, scarred, or unresponsive (e.g., **Asherman Syndrome** or **Genital Tuberculosis**). **Why other options are incorrect:** * **Hypothalamus (B) and Pituitary (A):** If the defect were at the level of the HPO axis (low GnRH or FSH/LH), the exogenous hormones provided in the test would have bypassed these levels and caused the endometrium to shed. A positive bleed in these cases would point toward hypothalamic/pituitary failure. * **Ovary (C):** Similarly, if the ovaries were failing (Premature Ovarian Failure), they would not be producing estrogen. However, the exogenous estrogen provided during the test would still cause the endometrium to proliferate and bleed. **High-Yield Clinical Pearls for NEET-PG:** * **Step 1:** Rule out pregnancy (most common cause of secondary amenorrhea). * **Step 2:** Progesterone Challenge Test (Checks endogenous estrogen and outflow tract). * **Step 3:** E+P Challenge Test (Checks endometrium/outflow tract patency). * **Asherman Syndrome:** The most common cause of a negative E+P challenge test in clinical practice. * **Genital TB:** A high-yield cause in the Indian context leading to end-stage uterine synechiae and a negative E+P test.

Q: What is the most common cause of spontaneous abortion?

Chromosomal abnormality. **Explanation:** **1. Why Chromosomal Abnormality is Correct:** Chromosomal abnormalities are the single most common cause of spontaneous abortion, accounting for approximately **50–60% of all first-trimester miscarriages**. The most frequent specific abnormality is **Autosomal Trisomy** (Trisomy 16 being the most common), followed by Monosomy X (Turner Syndrome) and Triploidy. These genetic errors usually occur de novo during gametogenesis or fertilization, leading to non-viable embryos that the body naturally rejects. **2. Why Other Options are Incorrect:** * **Uterine Malformations (B):** While conditions like a septate uterus or cervical incompetence are significant causes of recurrent pregnancy loss (RPL) and second-trimester abortions, they are statistically less common than genetic factors in overall spontaneous abortions. * **Immunological Factors (C):** Conditions like Antiphospholipid Syndrome (APLS) are crucial causes of recurrent miscarriage, but they represent a smaller percentage of isolated spontaneous abortions. * **Infections (D):** While TORCH infections or bacterial vaginosis can lead to pregnancy loss, they are infrequent causes of early spontaneous abortion compared to chromosomal errors. **3. NEET-PG Clinical Pearls:** * **Most common Trisomy in abortus:** Trisomy 16. * **Most common single chromosomal abnormality:** Monosomy X (45,X). * **Timing:** Genetic factors dominate in the **first trimester** (<12 weeks), whereas anatomical and maternal factors become more prominent in the second trimester. * **Recurrent Pregnancy Loss (RPL):** Defined as $\geq$ 2 consecutive spontaneous abortions; here, parental karyotyping and APLS screening become mandatory.

Q: A 16-year-old girl has not yet reached menarche. She has normal secondary sex characteristics, and visual inspection of her external genitalia is unremarkable. The patient is given progesterone and has withdrawal bleeding a few days later. What is the most likely diagnosis?

A constitutional delay in puberty. **Explanation:** The core concept in this case is the **Progesterone Challenge Test (PCT)**. A positive withdrawal bleed indicates two things: 1. The patient has an intact **outflow tract** (uterus, cervix, and vagina). 2. The patient has **adequate endogenous estrogen** to prime the endometrium. **Constitutional Delay in Puberty** is the most likely diagnosis because the patient has normal secondary sexual characteristics (indicating a functional Hypothalamic-Pituitary-Ovarian axis that has produced enough estrogen for breast development) and a positive PCT. In constitutional delay, the "biological clock" is simply set later, but the hormonal machinery is intact. **Analysis of Incorrect Options:** * **Primary Ovarian Disease (e.g., Premature Ovarian Failure):** These patients have low estrogen levels. Without estrogen priming, the endometrium does not proliferate, leading to a **negative** progesterone withdrawal bleed. * **Turner Syndrome (45,XO):** This is a form of hypergonadotropic hypogonadism characterized by streak ovaries. These patients typically present with primary amenorrhea, short stature, and a **lack** of secondary sexual characteristics/estrogen, resulting in a negative PCT. * **Destructive Hypothalamic Disorder:** Conditions like Kallmann syndrome or craniopharyngioma cause hypogonadotropic hypogonadism. The lack of GnRH leads to low FSH/LH and, consequently, low estrogen, resulting in a **negative** PCT. **Clinical Pearls for NEET-PG:** * **Positive PCT:** Confirms anovulation (usually PCOS or Constitutional Delay). * **Negative PCT:** Indicates either low estrogen (Hypothalamic/Ovarian failure) or an outflow tract obstruction (Asherman’s or Mullerian anomalies). * **Primary Amenorrhea Definition:** Absence of menarche by age 13 (no secondary sexual characteristics) or age 15 (with secondary sexual characteristics).

Q: Using histological criteria to date endometrial development, which of the following is the earliest sign of ovulation?

Glycogen accumulation. **Explanation:** The correct answer is **Glycogen accumulation**, specifically manifesting as **subnuclear vacuoles**. ### 1. Why Glycogen Accumulation is Correct In a typical 28-day menstrual cycle, ovulation occurs on Day 14. Following ovulation, the corpus luteum produces **progesterone**, which shifts the endometrium from the proliferative phase to the secretory phase. The earliest histological hallmark of this progesterone influence is the appearance of **subnuclear vacuoles** containing glycogen within the glandular epithelium. This occurs on **Day 16** (approximately 36–48 hours post-ovulation), making it the earliest reliable histological sign that ovulation has occurred. ### 2. Analysis of Incorrect Options * **A. Gland coiling:** While glands become increasingly tortuous (coiled) during the secretory phase, this process begins in the late proliferative phase and continues throughout the cycle. It is not a specific or earliest marker of ovulation. * **B. Stromal edema:** This is a characteristic feature of the mid-secretory phase, typically peaking around **Day 21–22**. It is a crucial sign for implantation but occurs much later than vacuole formation. * **C. Neovascularization:** The development of spiral arteries occurs throughout the secretory phase, becoming most prominent and coiled in the late secretory phase (Days 23–25). ### 3. NEET-PG High-Yield Pearls * **Noyes Criteria:** The classic method used for histological dating of the endometrium. * **Day 16:** Subnuclear vacuoles (Earliest sign). * **Day 17:** Nuclei are pushed to the center by basal vacuoles (palisading). * **Day 22:** Maximal stromal edema (Optimal time for implantation/“Implantation Window”). * **Day 24:** First appearance of pre-decidual changes around spiral arterioles. * **Key Hormone:** Progesterone is the "hormone of the secretory phase"; without ovulation, these changes do not occur.

Q: Which of the following is not a cause for primary amenorrhea?

Sheehan's syndrome. ### Explanation The key to answering this question lies in distinguishing between **primary** and **secondary** amenorrhea. Primary amenorrhea refers to the failure to initiate menses by age 15 (with secondary sexual characteristics) or age 13 (without them). Secondary amenorrhea is the cessation of menses for >3 months in a previously regular cycle. **Why Sheehan’s Syndrome is the correct answer:** Sheehan’s syndrome is **postpartum pituitary necrosis** caused by severe obstetric hemorrhage and hypotension. Since it occurs as a complication of childbirth, the patient must have been menstruating and fertile previously. Therefore, it is a classic cause of **secondary amenorrhea**, not primary. **Analysis of Incorrect Options:** * **Kallmann’s Syndrome:** A form of hypogonadotropic hypogonadism caused by failure of GnRH-secreting neurons to migrate. It presents with primary amenorrhea and anosmia. * **Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome:** Characterized by Müllerian agenesis (absent uterus and upper 2/3 of the vagina). It is the second most common cause of primary amenorrhea; patients have a 46,XX karyotype and normal secondary sexual characteristics. * **Turner Syndrome (45,XO):** The most common cause of primary amenorrhea. It involves gonadal dysgenesis (streak ovaries), leading to hypergonadotropic hypogonadism. **NEET-PG High-Yield Pearls:** * **Most common cause of primary amenorrhea:** Turner Syndrome (45,XO). * **Most common cause of secondary amenorrhea:** Pregnancy (always rule this out first!). * **Sheehan’s Syndrome clinical hint:** Look for a history of "failure to lactate" followed by "failure to resume menses" after a traumatic delivery. * **MRKH vs. AIS:** In MRKH, the karyotype is 46,XX (ovaries present); in Androgen Insensitivity Syndrome (AIS), the karyotype is 46,XY (testes present).

Q: Which of the following is NOT a contraindication for estrogen therapy?

Hypertension. **Explanation:** The core principle in prescribing Estrogen Therapy (ET) or Hormone Replacement Therapy (HRT) is identifying **estrogen-dependent pathologies** and **pro-coagulant risks**. **Why Hypertension is the Correct Answer:** Controlled hypertension is a **relative precaution**, not an absolute contraindication for estrogen therapy. While oral estrogens can slightly increase blood pressure via the stimulation of hepatic renin substrate (angiotensinogen), most women with well-controlled BP can safely use ET. In such cases, **transdermal patches** are preferred as they bypass the first-pass hepatic metabolism, minimizing the effect on the Renin-Angiotensin-Aldosterone System (RAAS). **Why the Other Options are Incorrect:** * **Breast Cancer:** Estrogen promotes the proliferation of mammary epithelium. A history of breast cancer is an **absolute contraindication** as it may stimulate the recurrence of micrometastases. * **Uterine (Endometrial) Cancer:** Estrogen causes endometrial hyperplasia. In women with an intact uterus, "unopposed estrogen" significantly increases the risk of endometrial carcinoma. A history of this malignancy precludes ET. * **Previous Thromboembolism:** Estrogen increases the synthesis of clotting factors (II, VII, IX, X) and decreases Antithrombin III. A history of DVT or Pulmonary Embolism is a major contraindication due to the high risk of recurrent thrombotic events. **NEET-PG High-Yield Pearls:** * **Absolute Contraindications to HRT:** Undiagnosed abnormal vaginal bleeding, known/suspected pregnancy, active liver disease, and hormone-dependent tumors. * **Route Matters:** Transdermal estrogen does not increase the risk of venous thromboembolism (VTE) to the same extent as oral estrogen. * **The "Window of Opportunity":** HRT is most beneficial and safest when started within 10 years of menopause or before age 60.

Question 1

Selective estrogen receptor modulators (SERMs) are used as add-back therapy concurrently with GnRH agonist to:

Accepted Answer

Prevent bone loss

Answer

Increase shrinkage of leiomyoma

Answer

Avoid vasomotor symptoms

Answer

Decrease venous thromboembolism risks

Question 2

Which of the following medications is NOT used for the management of hirsutism in females?

Accepted Answer

Oxandrolone

Answer

Spironolactone

Answer

Finasteride

Answer

Flutamide

Question 3

In a patient with secondary amenorrhea who fails to achieve withdrawal bleeding after estrogen and progesterone therapy, the primary cause lies at which level?

Accepted Answer

Endometrium

Answer

Pituitary

Answer

Hypothalamus

Answer

Ovary

Question 4

Superfoetation means:

Accepted Answer

Fertilization of a second ovum in an already pregnant woman

Answer

Fertilization of two ova of the same menstrual cycle by two different acts of coitus

Answer

Uniovular twin pregnancy

Answer

Fertilization of two ova of the same menstrual cycle by a single act of coitus

Question 5

What is the most common cause of spontaneous abortion?

Accepted Answer

Chromosomal abnormality

Answer

Uterine malformations

Answer

Immunological factors

Answer

Infections

Question 6

A 16-year-old girl has not yet reached menarche. She has normal secondary sex characteristics, and visual inspection of her external genitalia is unremarkable. The patient is given progesterone and has withdrawal bleeding a few days later. What is the most likely diagnosis?

Accepted Answer

A constitutional delay in puberty

Answer

Primary ovarian disease

Answer

Turner syndrome

Answer

A destructive hypothalamic disorder

Question 7

The maturation index on vaginal cytology is a diagnostic method for evaluating the:

Accepted Answer

Endocrine status of cervix

Answer

Adequacy of cytotoxic drug therapy

Answer

Gender of an anatomically abnormal child

Answer

Malignant change at squamocolumnar junction of cervix

Question 8

Using histological criteria to date endometrial development, which of the following is the earliest sign of ovulation?

Accepted Answer

Glycogen accumulation

Answer

Gland coiling

Answer

Stromal edema

Answer

Neovascularization

Question 9

Which of the following is not a cause for primary amenorrhea?

Accepted Answer

Sheehan's syndrome

Answer

Kallmann's syndrome

Answer

Mayer Rokitansky Kuster Hauser syndrome

Answer

Turner syndrome

Question 10

Which of the following is NOT a contraindication for estrogen therapy?

Accepted Answer

Hypertension

Answer

Uterine cancer

Answer

Breast cancer

Answer

Previous history of thromboembolism

Reproductive Endocrinology — MCQs

Reproductive Endocrinology — MCQs

On this page

Practice by Chapter

Want unlimited practice?